Is bortezomib ( Velcade ) , rituximab , cyclophosphamide , and dexamethasone combination regimen active as front-line therapy of low-grade non-Hodgkin lymphoma?
Although the number of studied patients is small, VRCD appears safe and active as front-line therapy for low-grade non-Hodgkin lymphoma. Further studies are justified.
These results are consistent with the conclusion that quarantine does not have negative psychological effects under these circumstances.